Dogwood Therapeutics
Logotype for Dogwood Therapeutics Inc

Dogwood Therapeutics (DWTX) investor relations material

Dogwood Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Dogwood Therapeutics Inc
Q3 2026 earnings summary5 Nov, 2026

Executive summary

  • Completed the 239-patient Halneuron® Phase 2b trial for chemotherapy-induced neuropathic pain (CINP); top-line results expected in November 2026.

  • Fully enrolled 95 patients in the 12-week open-label extension; completion expected in early 2027.

  • Cash of $4.9M at September 30 plus the $5.0M October placement is expected to fund operations through Q1 2027.

Financial highlights

  • Q3 licensing revenue was $100K, the first payment under the PRIDCor License Agreement; cost of goods sold was $88.1K and gross profit was $11.9K.

  • Q3 R&D expense was $3.3M vs. $14.5M YoY, primarily reflecting the prior-year $12.0M acquired IPR&D charge, partly offset by higher Halneuron® costs.

  • Q3 G&A expense was $1.6M vs. $1.3M YoY, primarily due to higher salaries and personnel costs.

  • Q3 operating expenses were $4.93M vs. $15.81M YoY; 9M expenses were $24.07M vs. $24.16M.

  • 9M R&D expense fell to $9.27M from $19.53M, primarily reflecting the prior-year acquired IPR&D charge, partly offset by higher Halneuron® trial costs.

Outlook and guidance

  • Halneuron® Phase 2b CINP top-line results are expected in November 2026; final data from the 12-week open-label extension are expected in early 2027.

  • SP16 IV Phase 1b patient dosing is projected to begin in the coming months; the initial safety trial is funded by an NCI grant.

  • Cash and October placement proceeds are expected to fund operations through Q1 2027; additional financing is needed beyond that period.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Dogwood Therapeutics earnings date

Logotype for Dogwood Therapeutics Inc
Q4 202617 Mar, 2027
Dogwood Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Dogwood Therapeutics earnings date

Logotype for Dogwood Therapeutics Inc
Q4 202617 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Dogwood Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative therapies targeting complex diseases. Utilizing advanced scientific research and proprietary technology platforms, the company aims to address unmet medical needs across therapeutic areas such as oncology, immunology, and infectious diseases. Dogwood Therapeutics is engaged in preclinical and clinical research, partnering with healthcare organizations and research institutions to advance potential treatments. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.